0
Disorders of the Pleura |

Different Concentrations of Lewis Lung Cancer (LLC) Cells in an Experimental Model of Malignant Pleural Disease

Lisete Teixeira, MD; Milena Acencio, MD; Evaldo Marchi, MD; Bruna Silva; Ricardo Terra; Juliana Puka; Francisco Vargas, MD; Vera Capelozzi, MD
Author and Funding Information

Pleura Laboratory, Pulmonary Division, Heart Institute (InCor) - University of Sao Paulo Medical School, Sao Paulo, Brazil


Chest. 2014;146(4_MeetingAbstracts):429A. doi:10.1378/chest.1994252
Text Size: A A A
Published online

Abstract

SESSION TITLE: Malignant Pleural Disease Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Malignant pleural effusion (MPE) poses a common and significant clinical problem. Its pathogenesis is still poorly understood and therapeutic options are limited. Animal models of MPE can help to show new aspects along with the pathological reasoning at the root of this condition. Stathopoulos et al in 2006 described a model of MPE using 1.5 x105 LLC cells placed directly into the pleural space of mice. They reported carcinomatosis which yielded pleural effusions, pleural tumors, and 100% mortality after 17 days. The objective was to determine the ideal concentration of LLC cells that will promote disease while allowing for longer survival time, with the aim of future research into pathogenesis and therapy.

METHODS: Sixty C57BL/6 mice were divided into groups receiving intrapleural injections of 0.1, 0.5 or 1.5 x 105 of LLC cells. Thirty animals were followed until death to develop a survival curve. Thirty mice were euthanized after 7, 14 or 21 days; weight, mobility, tumor presence in visceral pleura and pericardium, inflammatory cells or histological changes in lung parenchyma, kidney, liver and spleen were evaluated. Statistical analysis: One Way ANOVA, Kaplan-Meier curve, p<0.05.

RESULTS: The lowest survival time was observed in the group that received the highest concentration of LLC cells (p<0.05; 1.5 x 105 = 21 days, 0.5 x 105 = 26 days and 0.1 x 105 = 28 days). Twenty-one days after intrapleural injection of LLC cells, a significant weight reduction was observed in the 1.5 x 105 cell group (p<0.05). The decrease of mobility was more evident in the highest concentration. Tumor presence in the visceral pleura was observed in all groups and was proportional to the concentration and time since LLC cell instillation (p<0.05). Metastasis to the pericardium was more evident in concentrations of 1.5 x 105 cells. Inflammatory cells of the pulmonary parenchyma and histological changes in the kidneys, liver and spleen were noted in all groups with the highest scores in groups of 0.5 x 105 and 1.5 x 105 cells.

CONCLUSIONS: The experimental model of induced malignant pleural disease using a concentration of 0.5 x 105 of LLC cells produced the neoplastic changes found in the model previously described, but with a significant increase in survival time allowing this type of model to be better used in future research projects.

CLINICAL IMPLICATIONS: This model can be used as a tool for future research into pathogenesis as well as in the evaluation of new therapeutic strategies for malignant pleural diseases.

DISCLOSURE: The following authors have nothing to disclose: Lisete Teixeira, Milena Acencio, Evaldo Marchi, Bruna Silva, Ricardo Terra, Juliana Puka, Francisco Vargas, Vera Capelozzi

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543